Építés alatt – nem éles oldal
Belépés
Még nem keres résztvevőt itt: Egyesült ÁllamokKorai 1. fázis

MCE Molecular Imaging for Myocarditis

A legfontosabb adatok

Hol
Charlottesville (Egyesült Államok)A helyszín megnézése
Fázis
Korai 1. fázis

Helyszínek itt: Egyesült Államok

  • University of VirginiaCharlottesville, Egyesült ÁllamokContact: Jonathan Lindner, MDNo longer taking part

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

A vizsgálat adatai

Ki végzi
University of Virginia
Azonosító
NCT07538544
A regiszteradat frissítve
2026. augusztus 20.
Eredeti leírás
Inflammation of the heart (myocarditis) is a serious condition that can cause heart failure, abnormal heart rhythms, cardiac arrest, and death. Rapid diagnosis of this condition is key to reversing it. The purpose of this study is to determine whether myocarditis such as that which occurs with viral illness, autoimmune conditions, or certain therapies (i.e. immune checkpoint inhibitors) can be diagnosed using a new form of ultrasound imaging of the heart (echocardiography) that uses a contrast agent that is targeted to inflammation (Sonazoid).A teljes eredeti leírásKevesebb

MCE Molecular Imaging in Myocarditis

Inflammation of the heart (myocarditis) is a serious condition that can cause heart failure, abnormal heart rhythms, cardiac arrest, and death. Rapid diagnosis of this condition is key to reversing it. The purpose of this study is to determine whether myocarditis such as that which occurs with viral illness, autoimmune conditions, or certain therapies (i.e. immune checkpoint inhibitors) can be diagnosed using a new form of ultrasound imaging of the heart (echocardiography) that uses a contrast agent that is targeted to inflammation (Sonazoid).

Bevonási feltételek: Age ≥18 years of age; At least two of the following manifestations of myocarditis:; new or suspected new high-sensitivity troponin >3 times upper limit of normal; new or suspected new LV dysfunction with LVEF <50% or any segmental wall motion abnormality in the absence of prior ischemic event; ECG changes consistent with myocarditis defined as either diffuse ST elevation or ST-T abnormalities that are documented to be new,; unexplained severe ventricular arrhythmias,; Cardiac MR evidence for myocarditis; Predisposing condition or therapy associated with heightened risk of acute myocarditis (i.e. SARS-CoV-2, Parvovirus, Immune checkpoint inhibitors).

Kizáró feltételek: Treatment with potent immunosuppressive therapy beyond corticosteroids; Allergy to ultrasound contrast agents or eggs; Conditions associated with inflammatory myopathy (SLE, giant cell myocarditis, sarcoidosis, etc.); Inability to obtain consent; High pre-test likelihood for ACS based on ECG and history; Pregnancy or planned pregnancy; Lactation.

ClinicalTrials.gov NCT07538544